BioSpace News Archive

Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs announced that it is pushing ahead with its Anti-Coronavirus drug development program.

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first patients in its global Phase 3 trials of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D).

The Cardiac Center at Children’s Hospital of Philadelphia is pleased to announce the launch of Pediatric & Congenital Heart Talks, a free, monthly, video-based educational resource for clinical and research professionals in pediatric cardiology.

Celularity, Inc., a clinical-stage cell therapeutics company focused on the development of innovative allogeneic placenta-derived cellular therapies, announced today that the first patient was dosed in its Phase 1 clinical study of human placental hematopoietic stem cell-derived natural killer cells (CYNK-001) in adults with r

Company Expands Leadership Team as it Advances Preclinical Studies of rGDF11 in Stroke and Other Age-Related Diseases

Flirtey, the pioneer of the commercial drone delivery industry, and Vault Health, the pioneer of supervised COVID-19 testing, today announced a partnership to test drone delivery of the first FDA authorized saliva test for COVID-19.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the Company’s participation in Piper Sandler’s 32nd Annual Virtual Healthcare Conference.

The 7th International Focused Ultrasound Symposium organized by the U.S. Focused Ultrasound Foundation took place from 11/9 to 11/13 in virtual format this year due to the COVID-19 epidemic.

Therapeutics Solution International, Inc., (OTC Markets: TSOI), reported today clinical trial data demonstrating significant increases in natural killer cell activity in 12 healthy volunteers receiving daily QuadraMune™ as compared to controls taking placebo.

Oncopeptides AB, a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, announces that the company has finalized the program for the upcoming virtual capital markets day for investors, analysts and journalists on November 30th, 2020.